26 research outputs found

    ANÁLISE COMPARATIVA DO USO DA ESTATINA E DO ÁCIDO NICOTÍNICO NO TRATAMENTO DA SÍNDROME METABÓLICA

    Get PDF
    Considering metabolic syndrome (MS) as a pathophysiological condition characterized by arterial hypertension, central obesity, insulin resistance, dyslipidemia, and hyperglycemia, this study aims to compare the use of statins and nicotinic acid in the treatment of MS. To this end, a comparative analysis based on relevant clinical and epidemiological studies was conducted. Thus, it is observed that statins significantly reduce LDL cholesterol by about 50% and decrease the risk of cardiovascular events by 25% to 35%, with an odds ratio (OR) of improvement between 0.70 and 0.80. Statins are widely available and accessible, especially in generic versions, and have a relatively manageable adverse effect profile. In contrast, nicotinic acid reduces LDL cholesterol by 15% to 25%, increases HDL cholesterol, and reduces triglycerides, but with less consistent efficacy in preventing cardiovascular events (OR ranging from 0.90 to 1.10) and significant side effects, such as skin flushing and hepatotoxicity. The cost and availability of nicotinic acid are more limited compared to statins. It is concluded that statins are the preferred choice for the treatment of MS due to their robust efficacy and accessibility, while nicotinic acid may be considered in specific cases, with caution due to its adverse effects.Considerando a síndrome metabólica (SM) como uma condição fisiopatológica caracterizada por hipertensão arterial, obesidade central, resistência à insulina, dislipidemia e hiperglicemia, este estudo objetiva comparar o uso de estatinas e ácido nicotínico no tratamento da SM. Para tanto, procede-se a uma análise comparativa baseada em estudos clínicos e epidemiológicos relevantes. Desse modo, observa-se que as estatinas reduzem significativamente o LDL-colesterol em cerca de 50% e diminuem o risco de eventos cardiovasculares em 25% a 35%, com odds ratio (OR) de melhora entre 0,70 e 0,80. As estatinas são amplamente disponíveis e acessíveis, especialmente nas versões genéricas, e apresentam um perfil de efeitos adversos relativamente manejável. Em contraste, o ácido nicotínico reduz o LDL-colesterol em 15% a 25%, aumenta o HDL-colesterol e reduz os triglicerídeos, mas com uma eficácia menos consistente na prevenção de eventos cardiovasculares (OR variando de 0,90 a 1,10) e efeitos colaterais significativos, como rubor cutâneo e hepatotoxicidade. O custo e a disponibilidade do ácido nicotínico são mais limitados em comparação às estatinas. Conclui-se que as estatinas são a escolha preferida para o tratamento da SM devido à sua eficácia robusta e acessibilidade, enquanto o ácido nicotínico pode ser considerado em casos específicos, com precaução devido aos seus efeitos adversos

    ANÁLISE COMPARATIVA DO USO DE LISDEXANFETAMINA E DE METILFENIDATO NO TRATAMENTO DO TDAH

    Get PDF
      Considering the increasing prevalence of Attention Deficit Hyperactivity Disorder (ADHD) and the need for effective and safe therapeutic interventions, this research aimed to conduct a comparative analysis between lisdexamfetamine and methylphenidate in the treatment of ADHD. To this end, a comprehensive qualitative literature review was conducted, using sources such as Scielo, Google Scholar, scientific journals, institutional repositories, and virtual libraries, without specific time period limitations. Thus, it was observed that both medications demonstrated efficacy in reducing ADHD symptoms. Lisdexamfetamine showed a more prolonged and consistent effect on dopaminergic neurotransmission and a potentially more favorable side effect profile, with fewer reports of severe adverse effects compared to methylphenidate. Methylphenidate, in turn, showed significant efficacy, especially in the short term. It is concluded that both lisdexamfetamine and methylphenidate are valid therapeutic options for the treatment of ADHD, with specific advantages in different clinical contexts. The choice between these medications should consider the individual characteristics of patients and the available evidence of efficacy and safety, contributing to the optimization of treatment and the improvement of the quality of life of patients with ADHD.Considerando a crescente prevalência do Transtorno de Déficit de Atenção e Hiperatividade (TDAH) e a necessidade de intervenções terapêuticas eficazes e seguras, esta pesquisa objetivou realizar uma análise comparativa entre lisdexanfetamina e metilfenidato no tratamento do TDAH. Para tanto, procedeu-se a uma revisão bibliográfica qualitativa abrangente, utilizando fontes como Scielo, Google Acadêmico, revistas científicas, repositórios institucionais e bibliotecas virtuais, sem limitação de período específico. Desse modo, observou-se que ambos os medicamentos demonstraram eficácia na redução dos sintomas do TDAH. A lisdexanfetamina apresentou um efeito mais prolongado e consistente na neurotransmissão dopaminérgica e um perfil de efeitos colaterais potencialmente mais favorável, com menos relatos de efeitos adversos graves em comparação ao metilfenidato. O metilfenidato, por sua vez, mostrou eficácia significativa, especialmente em curto prazo. Conclui-se que tanto a lisdexanfetamina quanto o metilfenidato são opções terapêuticas válidas para o tratamento do TDAH, com vantagens específicas em diferentes contextos clínicos. A escolha entre esses medicamentos deve considerar as características individuais dos pacientes e as evidências de eficácia e segurança disponíveis, contribuindo para a otimização do tratamento e a melhoria da qualidade de vida dos pacientes com TDAH

    Pervasive gaps in Amazonian ecological research

    Get PDF
    Biodiversity loss is one of the main challenges of our time,1,2 and attempts to address it require a clear un derstanding of how ecological communities respond to environmental change across time and space.3,4 While the increasing availability of global databases on ecological communities has advanced our knowledge of biodiversity sensitivity to environmental changes,5–7 vast areas of the tropics remain understudied.8–11 In the American tropics, Amazonia stands out as the world’s most diverse rainforest and the primary source of Neotropical biodiversity,12 but it remains among the least known forests in America and is often underrepre sented in biodiversity databases.13–15 To worsen this situation, human-induced modifications16,17 may elim inate pieces of the Amazon’s biodiversity puzzle before we can use them to understand how ecological com munities are responding. To increase generalization and applicability of biodiversity knowledge,18,19 it is thus crucial to reduce biases in ecological research, particularly in regions projected to face the most pronounced environmental changes. We integrate ecological community metadata of 7,694 sampling sites for multiple or ganism groups in a machine learning model framework to map the research probability across the Brazilian Amazonia, while identifying the region’s vulnerability to environmental change. 15%–18% of the most ne glected areas in ecological research are expected to experience severe climate or land use changes by 2050. This means that unless we take immediate action, we will not be able to establish their current status, much less monitor how it is changing and what is being lostinfo:eu-repo/semantics/publishedVersio

    Pervasive gaps in Amazonian ecological research

    Get PDF

    Repercussão da terapia de suplementação de proteína em detrimento das alterações na composição muscular de idosos: uma revisão: Repercussion of protein supplementation therapy to the detriment of changes in muscle composition in the elderly: a review

    Get PDF
    INTRODUÇÃO: O ato de envelhecer traz consigo inúmeras mudanças fisiológicas, dentre elas, destaca-se a sarcopenia, que por vezes pode levar a perda da capacidade funcional, podendo prejudicar a mobilidade e por fim acarretar em acidentes graves ou mortes. A atual concentração diária recomendada de proteína por quilograma não foi projetada para uma população em fase de envelhecimento, o que pode levar a uma concentração de proteína insuficiente. A suplementação proteica surgiu como forma alternativa de preservar a manutenção muscular. OBJETIVO: Analisar os efeitos da suplementação proteica na manutenção da capacidade funcional muscular na população idosa. METODOLOGIA: Para tanto, foi realizada uma revisão integrativa da literatura de aspecto qualitativo, no qual, a partir de uma pesquisa em bases de dados selecionadas, baseou-se em estudos que apresentaram efeitos da suplementação proteica na manutenção da capacidade funcional muscular de idosos. Ao final foram selecionados seis estudos que contemplavam o tema em questão. RESULTADOS E DISCUSSÃO: A melhora do estado nutricional está relacionada ao desempenho muscular, com base nisso, foram analisados nos estudos os seguintes aspectos: ganho de massa muscular, exercício físico em jejum, membros inferiores, velocidade da marcha e outros parâmetros funcionais e 25-hidroxivitamina D, todos colocando-se em comparação com a suplementação proteica como forma intervencionista e de manutenção da capacidade funcional muscular. Ainda, foi realizada uma análise da suplementação dietética com aminoácidos de cadeia ramificada (BCAAs) em relação a desnutrição. CONCLUSÃO: A análise dos dados supracitados revelou a relevância da busca pela melhoria na qualidade de vida e bem-estar da população senil, de maneira que o consumo diário recomendado de proteína seja preconizado como principal medida para manutenção da massa muscular nesta parcela populacional. Deve-se estimular o consumo diário de alimentos ricos em proteínas, tais como carnes, ovos, leite e derivados e suplementos alimentares, quando sua prescrição se faz necessária. Diante da corroboração da sarcopenia no aumento da incidência de quedas em idosos, se faz necessário orientar e estimular a população senil para a prática regular de exercício físico resistido, além do acompanhamento de equipe multidisciplinar

    Pervasive gaps in Amazonian ecological research

    Get PDF
    Biodiversity loss is one of the main challenges of our time,1,2 and attempts to address it require a clear understanding of how ecological communities respond to environmental change across time and space.3,4 While the increasing availability of global databases on ecological communities has advanced our knowledge of biodiversity sensitivity to environmental changes,5,6,7 vast areas of the tropics remain understudied.8,9,10,11 In the American tropics, Amazonia stands out as the world's most diverse rainforest and the primary source of Neotropical biodiversity,12 but it remains among the least known forests in America and is often underrepresented in biodiversity databases.13,14,15 To worsen this situation, human-induced modifications16,17 may eliminate pieces of the Amazon's biodiversity puzzle before we can use them to understand how ecological communities are responding. To increase generalization and applicability of biodiversity knowledge,18,19 it is thus crucial to reduce biases in ecological research, particularly in regions projected to face the most pronounced environmental changes. We integrate ecological community metadata of 7,694 sampling sites for multiple organism groups in a machine learning model framework to map the research probability across the Brazilian Amazonia, while identifying the region's vulnerability to environmental change. 15%–18% of the most neglected areas in ecological research are expected to experience severe climate or land use changes by 2050. This means that unless we take immediate action, we will not be able to establish their current status, much less monitor how it is changing and what is being lost

    Pervasive gaps in Amazonian ecological research

    Get PDF
    Biodiversity loss is one of the main challenges of our time,1,2 and attempts to address it require a clear understanding of how ecological communities respond to environmental change across time and space.3,4 While the increasing availability of global databases on ecological communities has advanced our knowledge of biodiversity sensitivity to environmental changes,5,6,7 vast areas of the tropics remain understudied.8,9,10,11 In the American tropics, Amazonia stands out as the world's most diverse rainforest and the primary source of Neotropical biodiversity,12 but it remains among the least known forests in America and is often underrepresented in biodiversity databases.13,14,15 To worsen this situation, human-induced modifications16,17 may eliminate pieces of the Amazon's biodiversity puzzle before we can use them to understand how ecological communities are responding. To increase generalization and applicability of biodiversity knowledge,18,19 it is thus crucial to reduce biases in ecological research, particularly in regions projected to face the most pronounced environmental changes. We integrate ecological community metadata of 7,694 sampling sites for multiple organism groups in a machine learning model framework to map the research probability across the Brazilian Amazonia, while identifying the region's vulnerability to environmental change. 15%–18% of the most neglected areas in ecological research are expected to experience severe climate or land use changes by 2050. This means that unless we take immediate action, we will not be able to establish their current status, much less monitor how it is changing and what is being lost

    Rationale, study design, and analysis plan of the Alveolar Recruitment for ARDS Trial (ART): Study protocol for a randomized controlled trial

    Get PDF
    Background: Acute respiratory distress syndrome (ARDS) is associated with high in-hospital mortality. Alveolar recruitment followed by ventilation at optimal titrated PEEP may reduce ventilator-induced lung injury and improve oxygenation in patients with ARDS, but the effects on mortality and other clinical outcomes remain unknown. This article reports the rationale, study design, and analysis plan of the Alveolar Recruitment for ARDS Trial (ART). Methods/Design: ART is a pragmatic, multicenter, randomized (concealed), controlled trial, which aims to determine if maximum stepwise alveolar recruitment associated with PEEP titration is able to increase 28-day survival in patients with ARDS compared to conventional treatment (ARDSNet strategy). We will enroll adult patients with ARDS of less than 72 h duration. The intervention group will receive an alveolar recruitment maneuver, with stepwise increases of PEEP achieving 45 cmH(2)O and peak pressure of 60 cmH2O, followed by ventilation with optimal PEEP titrated according to the static compliance of the respiratory system. In the control group, mechanical ventilation will follow a conventional protocol (ARDSNet). In both groups, we will use controlled volume mode with low tidal volumes (4 to 6 mL/kg of predicted body weight) and targeting plateau pressure <= 30 cmH2O. The primary outcome is 28-day survival, and the secondary outcomes are: length of ICU stay; length of hospital stay; pneumothorax requiring chest tube during first 7 days; barotrauma during first 7 days; mechanical ventilation-free days from days 1 to 28; ICU, in-hospital, and 6-month survival. ART is an event-guided trial planned to last until 520 events (deaths within 28 days) are observed. These events allow detection of a hazard ratio of 0.75, with 90% power and two-tailed type I error of 5%. All analysis will follow the intention-to-treat principle. Discussion: If the ART strategy with maximum recruitment and PEEP titration improves 28-day survival, this will represent a notable advance to the care of ARDS patients. Conversely, if the ART strategy is similar or inferior to the current evidence-based strategy (ARDSNet), this should also change current practice as many institutions routinely employ recruitment maneuvers and set PEEP levels according to some titration method.Hospital do Coracao (HCor) as part of the Program 'Hospitais de Excelencia a Servico do SUS (PROADI-SUS)'Brazilian Ministry of Healt

    A IMPORTÂNCIA DA PSICOPROFILAXIA CIRÚRGICA PARA PACIENTES SUBMETIDOS A CIRURGIAS ELETIVAS

    No full text
    <p>INTRODUÇÃO: A psicoprofilaxia cirúrgica é uma técnica que tem como objetivo preparar psicologicamente o paciente para a cirurgia. A ansiedade pré-operatória é um problema comum que pode afetar negativamente a recuperação do paciente após a cirurgia. Estudos têm demonstrado que a psicoprofilaxia cirúrgica pode reduzir significativamente os níveis de ansiedade em pacientes submetidos a cirurgias eletivas. Ao reduzir a ansiedade, a psicoprofilaxia cirúrgica pode contribuir para uma cirurgia mais tranquila e segura, além de ajudar o paciente a lidar melhor com o período pós-operatório.</p&gt

    UPLC-MS-ESI-QTOF Analysis and Antifungal Activity of Aqueous Extracts of Spondias tuberosa

    No full text
    This study aimed to identify the chemical composition of the Spondias tuberosa aqueous leaf and root extracts (EALST and EARST) and to evaluate their effect, comparatively, against opportunistic pathogenic fungi. Ultra-Performance Liquid Chromatography Coupled to a Quadrupole/Time of Flight System (UPLC-MS-ESI-QTOF) was employed for chemical analysis. Candida albicans and C. tropicalis standard strains and clinical isolates were used (CA INCQS 40006, CT INCQS 40042, CA URM 5974, and CT URM 4262). The 50% Inhibitory Concentration for the fungal population (IC50) was determined for both the intrinsic action of the extracts and the extract/fluconazole (FCZ) associations. The determination of the Minimum Fungicidal Concentration (MFC) and the verification of effects over fungal morphological transitions were performed by subculture in Petri dishes and humid chambers, respectively, both based on micro-dilution. UPLC-MS-ESI-QTOF analysis revealed the presence of phenolic and flavonoid compounds. The association of the extracts with fluconazole, resulted in IC50 values from 2.62 µg/mL to 308.96 µg/mL. The MFC of the extracts was ≥16,384 µg/mL for all tested strains, while fluconazole obtained an MFC of 8192 µg/mL against C. albicans strains. A reduction in MFC against CA URM 5974 (EALST: 2048 µg/mL and EARST: 1024 µg/mL) occurred in the extract/fluconazole association
    corecore